Skip to main content
HAE logo
HAE
(NYSE)
Haemonetics Corporation
$72.87-- (--)
Loading... - Market loading

Haemonetics (HAE) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Haemonetics Corporation
HAENew York Stock ExchangeHealthcareMedical Devices

About Haemonetics

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Company Information

CEOChristopher Simon
Founded1971
IPO DateMay 9, 1991
Employees3,009
CountryUnited States
Fiscal YearApril - March

Stock Details

ExchangeNew York Stock Exchange (NYSE)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone781 848 7100
Address
125 Summer Street Boston, Massachusetts 02110 United States

Corporate Identifiers

CIK0000313143
CUSIP405024100
ISINUS4050241003
EIN04-2882273
SIC3841

Leadership Team & Key Executives

Christopher A. Simon
Chief Executive Officer, President and Director
Michelle L. Basil Esq., J.D.
Executive Vice President, General Counsel and Secretary
Roy Galvin
Executive Vice President and Chief Commercial Officer
Frank W. Chan Ph.D.
Executive Vice President and Chief Operating Officer
Farris Maryanne E. Maunsell
Vice President, Chief Accounting Officer and Principal Accounting Officer
Olga Guyette
Senior Director of Investor Relations
Rajeev Varma
Senior Vice President of Strategy and Corporate Development
Laurie A. Miller
Senior Vice President and Chief Human Resources Officer
Dr. Jan Hartmann M.D.
Senior Vice President and Chief Medical Officer
David J. Wilson
President of Plasma Business Unit